NCT00989313已完成不适用
A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on Non-head Locations (Trunk and Extremities) Who Have Completed Day 57 in Study PEP005-028 (REGION Ib)
Peplin17 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2009年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 17
- 主要终点
- Summarize treatment area recurrence of AK lesions, in the selected treatment area during a 12 month follow-up period for patients with complete clearance, who have completed Day 57 in Study PEP005-028.
研究概览
简要总结
This study is designed to follow up patients, who have participated in the PEP005-028 study and observed complete clearance of their Actinic Keratosis (AK) lesions, over a 12 month period to assess both recurrence of AK lesions and long term safety in the selected treatment area.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
干预措施: Lesion count (Drug)
结局指标
主要结局
Summarize treatment area recurrence of AK lesions, in the selected treatment area during a 12 month follow-up period for patients with complete clearance, who have completed Day 57 in Study PEP005-028.
时间窗: 12 months
次要结局
- Summarize long-term safety data, in the selected treatment area over a 12 month follow-up period for patients with complete clearance, who have completed Day 57 in Study PEP005-028.(12 months)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
不适用
Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE StudiesHepatitis CNCT01715779Novartis22
招募中
不适用
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel InjectionB-cell TumorsNCT06461351Juventas Cell Therapy Ltd.1,000
已完成
不适用
Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) PatientsPatients Transplanted With NiCord/CordIn (Omidubicel)NCT02039557Gamida Cell ltd33
终止
1 期
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3AchromatopsiaNCT03278873MeiraGTx UK II Ltd34
进行中（未招募）
3 期
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)2024-512580-31-00Sangamo Therapeutics Inc.20